TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma: next-generation sequencing results from the CONKO-001 trial
Purpose: We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. - Experimental Design: Patients of the CONKO-001 trial...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 31, 2020
|
| In: |
Clinical cancer research
Year: 2020, Jahrgang: 26, Heft: 14, Pages: 3732-3739 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-19-3034 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-19-3034 Verlag, lizenzpflichtig, Volltext: https://clincancerres.aacrjournals.org/content/26/14/3732 
|
| Verfasserangaben: | Marianne Sinn, Bruno V. Sinn, Denise Treue, Ulrich Keilholz, Frederik Damm, Rosa Schmuck, Philipp Lohneis, Frederick Klauschen, Jana K. Striefler, Marcus Bahra, Hendrik Bläker, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Hanno Riess, Jan Budczies, and Carsten Denkert |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1728972248 | ||
| 003 | DE-627 | ||
| 005 | 20230426165506.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200907s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-19-3034 |2 doi | |
| 035 | |a (DE-627)1728972248 | ||
| 035 | |a (DE-599)KXP1728972248 | ||
| 035 | |a (OCoLC)1341358744 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sinn, Marianne |d 1973- |e VerfasserIn |0 (DE-588)123598281 |0 (DE-627)706361822 |0 (DE-576)293783535 |4 aut | |
| 245 | 1 | 0 | |a TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma |b next-generation sequencing results from the CONKO-001 trial |c Marianne Sinn, Bruno V. Sinn, Denise Treue, Ulrich Keilholz, Frederik Damm, Rosa Schmuck, Philipp Lohneis, Frederick Klauschen, Jana K. Striefler, Marcus Bahra, Hendrik Bläker, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Hanno Riess, Jan Budczies, and Carsten Denkert |
| 264 | 1 | |c March 31, 2020 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 07.09.2020 | ||
| 520 | |a Purpose: We performed next-generation sequencing (NGS) in the CONKO-001 phase III trial to identify clinically relevant prognostic and predictive mutations and conducted a functional validation in The Cancer Genome Atlas (TCGA) sequencing data. - Experimental Design: Patients of the CONKO-001 trial received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherapy with gemcitabine (Gem) or observation only (Obs). Tissue samples of 101 patients were evaluated by NGS of 37 genes. Cox proportional hazard models were applied for survival analysis. In addition, functional genomic analyses were performed in an NGS and RNA-sequencing dataset of 146 pancreatic tumors from TCGA. - Results: The most common mutations in the CONKO cohort were KRAS (75%), TP53 (60%), SMAD4 (10%), CDKNA2 (9%), as well as SWI/SNF (12%) complex alterations. In untreated patients, TP53 mutations were a negative prognostic factor for disease-free survival (DFS; HR mut vs. WT 2.434, P = 0.005). With respect to gemcitabine treatment, TP53 mutations were a positive predictive factor for gemcitabine efficacy [TP53mut: HR for DFS Gem vs. Obs, 0.235 (0.130 - 0.423; P < 0.001); TP53wt: HR for DFS Gem vs. Obs, 0.794 (0.417 - 1.513; P = 0.483)] with a significant test for interaction (P = 0.003). In the TCGA dataset, TP53 mutations were associated with shortened DFS. - Conclusions: In CONKO-001, the benefit from adjuvant gemcitabine was confined to the TP53mut patient group. This potentially clinical relevant observation needs to be confirmed in independent prospective studies. The sensitivity of TP53mut PDAC to gemcitabine in CONKO-001 provides a lead for further mechanistic investigations. | ||
| 700 | 1 | |a Sinn, Bruno V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Treue, Denise |e VerfasserIn |4 aut | |
| 700 | 1 | |a Keilholz, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Damm, Frederik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schmuck, Rosa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lohneis, Philipp |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klauschen, Frederick |e VerfasserIn |4 aut | |
| 700 | 1 | |a Striefler, Jana K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bahra, Marcus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bläker, Hendrik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bischoff, Sven |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pelzer, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oettle, Helmut |e VerfasserIn |4 aut | |
| 700 | 1 | |a Riess, Hanno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Budczies, Jan |d 1970- |e VerfasserIn |0 (DE-588)124086403 |0 (DE-627)706532724 |0 (DE-576)186167679 |4 aut | |
| 700 | 1 | |a Denkert, Carsten |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research |d Philadelphia, Pa. [u.a.] : AACR, 1995 |g 26(2020), 14, Seite 3732-3739 |h Online-Ressource |w (DE-627)325489971 |w (DE-600)2036787-9 |w (DE-576)094502234 |x 1557-3265 |7 nnas |a TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma next-generation sequencing results from the CONKO-001 trial |
| 773 | 1 | 8 | |g volume:26 |g year:2020 |g number:14 |g pages:3732-3739 |g extent:8 |a TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma next-generation sequencing results from the CONKO-001 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1158/1078-0432.CCR-19-3034 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://clincancerres.aacrjournals.org/content/26/14/3732 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200907 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 124086403 |a Budczies, Jan |m 124086403:Budczies, Jan |d 910000 |d 912000 |d 50000 |e 910000PB124086403 |e 912000PB124086403 |e 50000PB124086403 |k 0/910000/ |k 1/910000/912000/ |k 0/50000/ |p 16 | ||
| 999 | |a KXP-PPN1728972248 |e 3747347096 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"8 S."}],"person":[{"display":"Sinn, Marianne","role":"aut","given":"Marianne","family":"Sinn","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Sinn","display":"Sinn, Bruno V.","role":"aut","given":"Bruno V."},{"given":"Denise","role":"aut","display":"Treue, Denise","roleDisplay":"VerfasserIn","family":"Treue"},{"given":"Ulrich","role":"aut","display":"Keilholz, Ulrich","roleDisplay":"VerfasserIn","family":"Keilholz"},{"roleDisplay":"VerfasserIn","family":"Damm","role":"aut","display":"Damm, Frederik","given":"Frederik"},{"roleDisplay":"VerfasserIn","family":"Schmuck","given":"Rosa","display":"Schmuck, Rosa","role":"aut"},{"role":"aut","display":"Lohneis, Philipp","given":"Philipp","family":"Lohneis","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Klauschen","given":"Frederick","display":"Klauschen, Frederick","role":"aut"},{"given":"Jana K.","display":"Striefler, Jana K.","role":"aut","family":"Striefler","roleDisplay":"VerfasserIn"},{"family":"Bahra","roleDisplay":"VerfasserIn","given":"Marcus","display":"Bahra, Marcus","role":"aut"},{"family":"Bläker","roleDisplay":"VerfasserIn","display":"Bläker, Hendrik","role":"aut","given":"Hendrik"},{"family":"Bischoff","roleDisplay":"VerfasserIn","display":"Bischoff, Sven","role":"aut","given":"Sven"},{"given":"Uwe","display":"Pelzer, Uwe","role":"aut","family":"Pelzer","roleDisplay":"VerfasserIn"},{"given":"Helmut","role":"aut","display":"Oettle, Helmut","family":"Oettle","roleDisplay":"VerfasserIn"},{"family":"Riess","roleDisplay":"VerfasserIn","given":"Hanno","role":"aut","display":"Riess, Hanno"},{"roleDisplay":"VerfasserIn","family":"Budczies","display":"Budczies, Jan","role":"aut","given":"Jan"},{"family":"Denkert","roleDisplay":"VerfasserIn","display":"Denkert, Carsten","role":"aut","given":"Carsten"}],"name":{"displayForm":["Marianne Sinn, Bruno V. Sinn, Denise Treue, Ulrich Keilholz, Frederik Damm, Rosa Schmuck, Philipp Lohneis, Frederick Klauschen, Jana K. Striefler, Marcus Bahra, Hendrik Bläker, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Hanno Riess, Jan Budczies, and Carsten Denkert"]},"relHost":[{"pubHistory":["1.1995 -"],"corporate":[{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"American Association for Cancer Research"}],"recId":"325489971","id":{"eki":["325489971"],"zdb":["2036787-9"],"issn":["1557-3265"]},"title":[{"title_sort":"Clinical cancer research","title":"Clinical cancer research"}],"disp":"TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma next-generation sequencing results from the CONKO-001 trialClinical cancer research","note":["Gesehen am 08.06.2023","Fortsetzung der Druck-Ausgabe"],"part":{"extent":"8","year":"2020","pages":"3732-3739","text":"26(2020), 14, Seite 3732-3739","issue":"14","volume":"26"},"name":{"displayForm":["American Association for Cancer Research"]},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"origin":[{"publisher":"AACR","dateIssuedDisp":"1995-","dateIssuedKey":"1995","publisherPlace":"Philadelphia, Pa. [u.a.]"}],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"March 31, 2020"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"1728972248","id":{"eki":["1728972248"],"doi":["10.1158/1078-0432.CCR-19-3034"]},"title":[{"subtitle":"next-generation sequencing results from the CONKO-001 trial","title_sort":"TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma","title":"TP53 mutations predict sensitivity to adjuvant gemcitabine in patients with pancreatic ductal adenocarcinoma"}],"note":["Gesehen am 07.09.2020"]} | ||
| SRT | |a SINNMARIANTP53MUTATI3120 | ||